Otonomy named Dean Hakanson, MD, CMO.
Dr. Hakanson, an anesthesiologist, has more than 16 years of experience in medical affairs, market access and health economic research. He most recently served as the vice president and head of health economics & outcomes research for U.S. medical and drug regulatory affairs at Novartis. He has also previously worked as vice president of healthcare access at Bristol-Myers Squibb.
Dr. Hakanson is a diplomat of the American Board of Anesthesiology and American Society of Anesthesiologists.
Otonomy is a clinical-stage biopharmaceutical company focusing on the development and commercialization of therapies for diseases and disorders of the ear.